Clinical Trials Browser

INDUSTRY × Hodgkin Disease × umbralisib × Clear all

NCT01767766 2021-08-23

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1 Completed

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Phase 1 Completed

Hodgkin Disease